Ipsen tries again in Parkinson's disease with $363m IRLAB de...

French drugmaker Ipsen has made another foray into the Parkinson's disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden's IRLAB for $28 million upfront.